

13 27. (amended) The immunogenic peptide of any of claims [1, 9,] 15 or 22

D2 wherein said peptide is recognized by HLA-A2 restricted tumor infiltrating lymphocyte.

29. (amended) A pharmaceutical composition comprising gp100 (SEQ ID NO:27 or the peptides of claim 15 or claim 22 and an acceptable excipient, diluent or carrier.

D3 30. (amended) A method of treating melanoma in a mammal comprising administering a [the] pharmaceutical composition comprising gp100 (SEQ ID NO:27) or an immunogenic peptide fragment thereof to [a] said mammal in an effective amount to stimulate the production of immune cells.

31. (amended) An immunogenic composition for immunizing a mammal comprising gp100 (SEQ ID NO:27 or a peptide according to claim 15 or claim 22 in a pharmacologically acceptable carrier.

REMARKS

Applicants respectfully request entry of the instant amendment and reconsideration of the claims in view of the following remarks.

Claims 15-31 are pending in the present application. The amendment of claim 15 finds support in the instant specification, *inter alia*, on pages 9-10.

Claims 15-16 and 27-28 have been rejected as being anticipated by Maresh (*DNA and Cell Biol.* 13:87 (1994)). Applicants respectfully disagree with the rejection.